Introduction
Cerebrovascular disease is a risk factor for impaired cognitive functioning. Approximately one-quarter of patients remain demented 3 months after a stroke. If selected impaired cognitive functions are considered, 50±75% of stroke patients are found to be affected, depending on age [1 . . ,2,3 . ]. Even among patients who remain cognitively intact after their index stroke, hospital-based and population-based studies [4, 5] have revealed a signi®cant risk for developing delayed dementia. However, physical handicaps rather than cognitive de®cits attract most attention after stroke, and sufferers of strokes that merely affect cognition frequently do not receive medical treatment at all.
Irrespective of the type of dementia, population-based studies yield extremely diverse data when different criteria for dementia are applied. According to the criteria of the International Classi®cation of Disease, 10th edition, 3.1% of the population older than 65 years is demented; according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-III criteria, however, the proportion is almost 10 times greater (29.1%) [6] . The criteria of the International Classi®cation of Disease, 10th edition, refer to the essential features of dementia, which comprise acquired, chronic and irreversible impairment of thinking and memory [7] . In contrast, DSM-IV is based on a much less re®ned concept [8] . This presents particular dif®culties when those criteria are applied to cognitive inabilities of vascular origin. Location-speci®c cognitive de®cits, such as aphasia, apraxia or agnosia, do not represent global intellectual dysfunction, even when they exist in various combinations. Clearly, such focal neurological dysfunctions should not be classi®ed as dementia, and are not addressed in the present review.
The pathogenic concept of vascular dementia
The classic concept implies that dementia of vascular origin is the result of a critical volume of infarcted brain tissue, irrespective of its topography [9] . However, isolated but strategically positioned lesions may also lead to signi®cant cognitive decline, even when they are of small volume [10] . In addition, poststroke dementia is well documented in patients with extensive subcortical white matter lesions [11] . On the basis of the current pathological and functional imaging data, three pathogenic concepts of vascular dementias (VaDs) have been described [12, 13 . ]: accumulated cortical infarcts; strategic subcortical infarcts; and functional cortical disconnection.
Accumulated cortical infarcts
Certain cortical lesions may generate de®ned cognitive signs and symptoms (amnesia, aphasia, apraxia, alexia, agraphia 
].
In evidence-based medicine, a reliable test is required to identify a particular disease with suf®cient sensitivity and speci®city. This requires a`gold standard', and to date none is available for the diagnosis of VaD [36
. . ]. In contrast to AD, a blinded pathologist is unable to determine reliably whether a vascular lesion was causal, contributory, or simply coincidental to a dementia syndrome. In the absence of such a gold standard in the diagnosis of VaD, data on the differential accuracies of the referred clinical criteria remain controversial and of limited value for the clinician [41±45].
Despite differences in the pro®le of cognitive decline between patients with VaD and those with AD, it is still uncertain whether patients may be reliably discriminated on the basis of those differences alone. Because motor symptoms are absent in AD until the late stages and are common in patients with VaD, these may represent a more accurate discriminating criterion. When infarcts or WMLs are present on computed tomography (CT) or MRI, they may only be incidental ®ndings or may explain the dementia. Such considerations are also of importance in patients with possible diffuse Lewy body disease, in whom a¯uctuating course may suggest VaD, and in patients with possible subcortical arteriolosclerotic encephalopathy (SAE), who may present with a similar clinical course.
Because of the heterogeneous pathophysiology and pathology of VaD, diagnostic criteria for VaD might never be simple. The primary degenerative and vascular diseases in the elderly are often combined, however, and therefore the diagnosis of VaD will probably become more valid when speci®c diagnostic tests for the different degenerative diseases become available.
Neuroimaging
Diagnostic accuracy can be enhanced by the additional use of brain imaging techniques, and they are an integral part of some of the more recent diagnostic criteria of VaD (Table 1) . Whereas both CT and MRI are equally reliable in detecting large artery ischaemic brain lesions, MRI is clearly superior with respect to small vessel disease and deep WMLs.
The frequency of WMLs (also known as leukoaraiosis) increases with age and increased blood pressure [46, 47] . Also, among patients with small vessel strokes the presence of leukoaraiosis indicates a poor prognosis with an increased risk for stroke recurrence and dementia [48, 49 . ]. Several studies have tried to establish a semiquantitative relation between the extension of WMLs and cognitive impairment. Various threshold volumes (e.g. 410 cm 2 in area or 40.5±4% of intracranial volume) beyond which cognitive impairment might become clinically apparent have been reported [36 . . , 50, 51] . If such a relation holds true is questionable, however.
The periventricular and deep white matter receive their blood supply through narrow penetrating endarterioles that are subject to small vessel disease. Thus, WMLs may primarily re¯ect chronic hypoperfusion and are regarded as major markers of brain tissue at risk rather than of cognitive impairment [36
. . ]. This is supported by the fact that there are patients with even widespread and con¯uent WMLs who do not have cognitive dysfunction. This requires a discrimination of the clinical syndrome SAE (Binswanger's disease) from the radiological diagnosis leukoaraiosis. The following criteria have been suggested for the diagnosis of SAE [45] : dementia; leukoaraiosis on CT or MRI; and two of the following three characteristics ± presence of a vascular risk factor or evidence of systemic vascular disease, evidence of focal cerebrovascular disease, and evidence of subcortical cerebral dysfunction (gait disorder, urinary incontinence).
Stroke, depression and cognitive impairment
Irrespective of cerebrovascular disease, affective disorders and cognitive functioning are known to be interrelated [52±54] . Depression is also a common sequelae in stroke, with a reported frequency of up to 65% of all patients [55±58]. This raises the critical question of whether depression and cognitive impairment after stroke evolve independently, or simply cause each other. Prior trials failed to ®nd a positive correlation between successful treatment of poststroke depression and improved cognitive functioning [59±61]. This resulted in the hypothesis that cognitive de®cits are the cause rather than the consequence of postroke depression [59, 62 . ]. In contrast, one recent, doubleblind, controlled nortriptyline trial [63 . ] revealed that depressive stroke patients gained improved cognitive functions after successful treatment of their mood disorder. Another intriguing detail of that study is that those patients whose depression responded to placebo also improved in cognitive tasks. This might imply that the mechanism of depression, and not that of nortriptyline itself, was responsible for the observed cognitive improvements. That trial thus refutes the hypothesis that cognitive de®cits cause poststroke depression, but supports the reverse contention that depression (among other mechanisms) adds to cognitive impairment in stroke patients.
Another issue is how the lesion site in¯uences poststroke depression and cognition. A number of studies reported a signi®cantly stronger relation in left as compared with right hemisphere strokes [59, 64, 65] . This has also been addressed in a recent prospective study [66 . ] that evaluated the relations between aphasia, depression and nonverbal cognitive functioning in a large series of stroke patients. The major ®nding of that study was a high susceptibility of aphasic patients to major depression; this continued to increase over the 1-year study period. Moreover, the data also revealed a signi®cant association between aphasia and nonverbal cognitive de®cits. Those ®nd-ings suggest that cognitive de®cits in aphasic patients do not simply re¯ect the linguistic disorder, but rather re¯ect a more complex impairment of the memory process [67] .
Therapeutic approach
Drug therapy for cognitive impairment following cerebrovascular disease must focus on at least two diverse targets, namely stroke prevention and speci®c interventions to improve cognitive functioning.
Preventive measures
Preventive measures comprise risk factor modi®cation and both primary and secondary stroke prevention. Although the majority of vascular risk factors are not modi®able, hypertension and hyperlipidaemia are. Several controlled trials [68, 69] con®rmed a signi®cant reduction in both initial and recurrent strokes with suf®cient antihypertensive therapy. Cholesterol (i.e. lowdensity lipoprotein)-lowering drugs are also successful in preventing stroke [70] . Furthermore, several lines of evidence have con®rmed that antiaggregant and antithrombotic drugs are effective in primary and/or secondary stroke prevention, as is surgical carotid artery management in selected patients [71±73] .
Only very few data are available regarding the direct impact of controlling vascular risk factors on cognitive improvement itself. A single small observational study [74] suggested that maintaining systolic blood pressure within the range 135±150 mmHg results in stabilization of cognitive functioning, whereas lowering the blood pressure to below this range would be associated with decline. Those data received support from the larger and much more recent Baltimore Longitudinal Study on Aging [75] . 
Conclusion
Stroke-related cognitive dysfunction is surrounded by many problems with respect to heterogeneity, relevance, prevalence and uniqueness. There is no consistent phenotype because strokes can strike any region of the brain. Moreover, it is dif®cult to establish a causal link between stroke and dementia, or to exclude the possibility that AD is responsible for the cognitive dysfunction. De®ning the term`vascular dementia' is a challenge that presents problems in establishing an appropriate medical de®nition, in conducting epidemiological and interventional studies, and in providing best care. The conceptual change in the approach to cognitive impairment of vascular origin was intended to recognize that several vascular mechanisms and many vascular diseases may lead to dementia. Patients with small-vessel disease are not the same as those with cardioembolic strokes or large vessel occlusive disease. White matter changes are more likely to occur in patients with chronic hypertension. Thus, from a nosological point of view, VaD is a highly heterogeneous issue that, in most cases, does not yet ®nd adequate re¯ection in clinical practice. 186±193. This is a well designed study of the clinically crucial issue of reliability and validity of various diagnostic concepts of VaD.
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